155 related articles for article (PubMed ID: 23770369)
1. Development of humanized rabbit monoclonal antibodies against vascular endothelial growth factor receptor 2 with potential antitumor effects.
Yu Y; Lee P; Ke Y; Zhang Y; Chen J; Dai J; Li M; Zhu W; Yu GL
Biochem Biophys Res Commun; 2013 Jul; 436(3):543-50. PubMed ID: 23770369
[TBL] [Abstract][Full Text] [Related]
2. A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models.
Yu Y; Lee P; Ke Y; Zhang Y; Yu Q; Lee J; Li M; Song J; Chen J; Dai J; Do Couto FJ; An Z; Zhu W; Yu GL
PLoS One; 2010 Feb; 5(2):e9072. PubMed ID: 20140208
[TBL] [Abstract][Full Text] [Related]
3. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
4. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
5. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
Li J; Huang S; Armstrong EA; Fowler JF; Harari PM
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1477-85. PubMed ID: 16029810
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
Zhu Z; Hattori K; Zhang H; Jimenez X; Ludwig DL; Dias S; Kussie P; Koo H; Kim HJ; Lu D; Liu M; Tejada R; Friedrich M; Bohlen P; Witte L; Rafii S
Leukemia; 2003 Mar; 17(3):604-11. PubMed ID: 12646950
[TBL] [Abstract][Full Text] [Related]
8. Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library.
Popkov M; Jendreyko N; Gonzalez-Sapienza G; Mage RG; Rader C; Barbas CF
J Immunol Methods; 2004 May; 288(1-2):149-64. PubMed ID: 15183093
[TBL] [Abstract][Full Text] [Related]
9. A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts.
Yu Y; Chen Y; Ding G; Wang M; Wu H; Xu L; Rui X; Zhang Z
Biochem Biophys Res Commun; 2015 Aug; 464(1):154-60. PubMed ID: 26093299
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor receptor-2 inhibition in experimental murine colitis.
Knod L; Donovan EC; Chernoguz A; Crawford KM; Dusing MR; Frischer JS
J Surg Res; 2013 Sep; 184(1):101-7. PubMed ID: 23688787
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
14. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
15. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
Prewett M; Huber J; Li Y; Santiago A; O'Connor W; King K; Overholser J; Hooper A; Pytowski B; Witte L; Bohlen P; Hicklin DJ
Cancer Res; 1999 Oct; 59(20):5209-18. PubMed ID: 10537299
[TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
17. Production of neutralizing monoclonal antibody against human vascular endothelial growth factor receptor II.
Li R; Xiong DS; Shao XF; Liu J; Xu YF; Xu YS; Liu HZ; Zhu ZP; Yang CZ
Acta Pharmacol Sin; 2004 Oct; 25(10):1292-8. PubMed ID: 15456530
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
Tonra JR; Deevi DS; Corcoran E; Li H; Wang S; Carrick FE; Hicklin DJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2197-207. PubMed ID: 16609035
[TBL] [Abstract][Full Text] [Related]
19. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
20. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
